Septerna (SEPN) struck a deal with Novo Nordisk (NVO) for $2.2 billion for obesity medications. Stay up to date on the latest market action, minute-by-minute, with Yahoo Finance's Market Minute.

Septerna reported a net loss for $(21.5m) in Q1 2025, versus a net loss of $(14.2m) in the prior year period, and reported a cash position of $398m, down from $421m in Q1 2024.

--Septerna, Inc., a biotechnology company pioneering a new era of G protein-coupled receptor drug discovery, today highlighted key business updates and upcoming milestones and reported financial ...

On October 28, one insider acquired $68.91 million worth of Septerna, Inc. (NASDAQ:SEPN) shares at a price of $18 per share. Currently, the stock is trading at $6.16 having lost 73.10% since the ...

Septerna has landed a $200 million deal with Novo Nordisk to develop oral weight-loss and diabetes drugs, with potential for $2 billion more in milestone payments. San Francisco Business Times.

Since Septerna’s inception in 2019, the company had raised $224.2 million prior to the IPO, most recently a $150 million Series B round last year led by RA Capital Management.That firm holds a 7 ...

Septerna, Inc. ( (SEPN) ) has released its Q3 earnings. Here is a breakdown of the information Septerna, Inc. presented to its investors. Septerna, Inc. is a clinical-stage biotechnology company ...

Septerna's shares rose about 31% in their market debut on Friday, giving the Goldman Sachs-backed biotech firm a valuation of $970 million. Skip to main content. Exclusive news, ...

The deal with U.S. biotech Septerna will see the companies develop pills to treat obesity, type 2 diabetes and other cardiometabolic diseases. Novo will cover all research-and-development costs ...

About Septerna Inc. Septerna, Inc. is a clinical-stage biotechnology company, which engages in pioneering a new era of G protein-coupled receptor oral small molecule drug discover ...

Septerna is also eligible to receive tiered royalties on global net sales of marketed products. Novo Nordisk will cover all R&D expenses for partnered programs under the collaboration.